PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-1.12%
Both companies show declining cash positions (-1.12% vs AVXL's -52.73%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Below half of AVXL's -52.73%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Below half of AVXL's -45.20%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Below half of AVXL's -48.85%. Michael Burry sees a potential red flag for stagnation or capital shortage.
36.86%
Higher Accounts Payable Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.96%
Above 1.5x AVXL's 16.97%. Michael Burry sees a red flag for liquidity risk vs. competitor.
4.78%
Higher Long-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.78%
Higher Total Non-Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
10.65%
Less than half of AVXL's 21.76%. David Dodd sees far fewer liability expansions relative to competitor.
382.94%
Above 1.5x AVXL's 0.63%. Michael Burry suspects heavy new equity expansion or dilution.
-3.62%
Below half AVXL's -18.83%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
382.94%
Less than half of AVXL's 1355.04%. David Dodd notes simpler yoy equity changes vs. competitor.
-10.94%
Below half AVXL's -42.62%. Michael Burry sees potential underperformance in building shareholder capital.
-1.12%
Below half AVXL's -48.85%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
4.78%
Less than half of AVXL's -0.68%. David Dodd sees less overall debt expansion vs. competitor.
4.98%
Less than half of AVXL's 21.02%. David Dodd sees better deleveraging or stronger cash buildup than competitor.